Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
Past Issue

Vol. 12, No. 3
March 2006

EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Comments Comments



Appendix 2 References
Appendix 1
Back to article

Perspective

Cost-effectiveness of West Nile Virus Vaccination

Armineh Zohrabian,*Comments Edward B. Hayes,† and Lyle R. Petersen†
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; and †Centers for Disease Control and Prevention, Fort Collins, Colorado, USA


Appendix 2. Discounting, Lifetime Disability Costs, and Costs due to Death

Discounting is an economic notion that even in a world of zero inflation, a dollar today would be of higher value to a person than a dollar in the future. The premium placed on benefits today versus the future is reflected in the rate at which a person is willing to exchange present for future costs and benefits. This quantitative measure of time preference is called the discount rate. When the costs or benefits under the study continue in the future, to make them comparable in terms of the time dimension economists calculate the present value of these costs or benefits by using discount rates. Different discount rates have been used in the literature: conceptually the appropriate discount rate depends on the perspective of the study and the question it poses. The US Public Health Service Panel on Cost-effectiveness in Health and Medicine recommends a 3% discount rate for economic studies in health (1).

The average societal cost due to death from West Nile virus (WNV) disease was estimated by using productivity loss tables (2) (we adjusted the costs from 2000 dollars to 2004 dollars) and the age distribution of 713 WNV nationwide deaths reported to the ArboNET database of the Centers for Disease Control and Prevention (CDC) since 1999 (CDC 2005, unpub. data). We estimated these costs both at a 5% and a 3% discount rates and, following the recommendations by the US Public Health Service Panel on Cost-effectiveness in Health and Medicine (1), we used the 3% discount rate estimate in our model, which yielded a death cost of $200,000 in 2004 dollars (at a 5% discount rate the death cost was $170,000 in 2004 dollars).

As a proxy for lifetime disability costs due to WNV illness, because of insufficient data, we used the lifetime costs of stroke available from the literature (3). Although the disability cost of stroke may underestimate the disability cost due to WNV because the median age for WNV neuroinvasive patients is lower (64 years of age [4]) than the median age of persons disabled due to stroke (76 years of age [5]), this will not have significant effect on the results because the cost-effectiveness ratio was not sensitive to changes in the cost of disability. The estimate of the cost of disability due to stroke in 1990 dollars was discounted at a 5% rate. We converted this estimate to 2004 dollars by using the Consumer Price Index for medical care (6) and the average hourly earnings of production workers (7). This estimate was ≈$180,000 in 2004 dollars.

To make the lifetime disability costs and the death costs comparable, we used the ratio of the 3% discounted death cost ($200,000) and the 5% discounted death cost ($170,000) as a multiplier for adjusting the disability cost discounted at a 5% ($180,000) to a disability cost discounted at 3%. The result was $210,000 in 2004 dollars, which we used as an estimate for a 3% discounted disability cost.

Appendix 2 References

  1. Corso PS, Haddix AC. Time effects. In: Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness. 2nd ed. New York: Oxford University Press; 2003. p. 94–5.
  2. Grosse SD. Appendix I. Productivity loss tables. In: Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness. 2nd ed. New York: Oxford University Press; 2003. p. 255–7.
  3. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459–66.
  4. O'Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis. 2004;4:61–70.
  5. Kalra L, Evans A, Perez I, Melbourn A, Patel A, Knapp M, Donaldson N. Training carers of stroke patients: randomised controlled trial. BMJ. 2004;328:1099.
  6. Bureau of Labor Statistics. US Department of Labor. Consumer price index—all urban consumers. Medical Care. 2003 [cited 2005 May 20]. Available from http://www.bls.gov/cpi/home.htm
  7. Bureau of Labor Statistics. US Department of Labor. National employment, hours and earnings. 2004 [cited 2005 May 20]. Available from http://www.bls.gov/ces/home.htm
   
     
   
Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Armineh Zohrabian, Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop K67, Atlanta, GA 30341, USA; fax: 770 488-5965; email: abz8@cdc.gov

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Return email address optional:


 


Comments to the EID Editors
Please contact the EID Editors at eideditor@cdc.gov

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page posted February 1, 2006
This page last reviewed February 22, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention